Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and chemotherapy in resectable HNSCC
NCT05980702Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen Memorial Hospital. Started Apr 2023; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05980702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980702.